Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines
Research Article
[키워드] age and gender
antibodies
antibody
antibody kinetics
Antibody Response
average
binding domain
BNT162b2
BNT162b2 vaccine
changes in
clinically
clinician
Cohort
COVID-19
COVID-19 pandemic
defined
difference
dosage
dose regimen
elicited
first dose
Follow-up
human cell
IgG
IgG antibody
IgG response
immune system
immunization
immunosuppressive drugs
linear
Moderna
mRNA
mRNA platform
mRNA vaccine
mRNA-1273
mRNA-1273 vaccine
overcome
participant
peaked
Pfizer/BioNTech
powerful tool
Prospective
regimens
regression modeling
remained
response
S-protein
SARS-CoV-2
SARS-CoV-2 vaccine
second dose
seroconverted
serological
Serologically
seronegative participants
significantly higher
Spike protein
the SARS-CoV-2
the vaccine
titer
translated
vaccination
Vaccine
Vaccines
virus spike protein
was used
were measured
[DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1128/Spectrum.01162-21 PMC 바로가기 [Article Type] Research Article